• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Latest News

Image of a doc reviewing a case report | Image Credit: fedrunovan - stock.adobe.com
CLL Followed by CML: A Rare Case Described

May 8th 2024

A very unusual case of 2 chronic leukemias, chronic lymphocytic leukemia (CLL) and secondary chronic myeloid leukemia (CML) existing simultaneously in an older patient was treated with a pair of targeted kinase inhibitors.

Enhanced image of leukemia | Image Credit: freshidea - stock.adobe.com
Targeted Therapies for CLL Can Lead to Improved Patient Outcomes

May 2nd 2024

CLL on a keyboard | Image Credit: momius - stock.adobe.com
Research Unveils UGT2B17 as Key Prognostic Marker in CLL

April 26th 2024

CLL cells in blood flow - Laszlo-stock.adobe.com
Long-Term, Real-World Data Support Ibrutinib Efficacy, Safety in CLL

April 24th 2024

Leukemia word bubble | Image Credit: chrupka - stock.adobe.com
Survival Rates in CLL: Targeted Agents vs Fludarabine Combo Therapy Study

April 17th 2024

More News

Jaypirca | Image credit: Eli Lilly

FDA Grants Accelerated Approval to Pirtobrutinib for Patients With CLL/SLL After Use of BTK, BCL-2 Inhibitors

Mary Caffrey
December 2nd 2023

The therapy is already approved for certain patients with relapsed/refractory mantle cell lymphoma.

Read More

Emory’s Jonathan Cohen, MD, Traces Evolution in CLL Therapy

Emory’s Jonathan Cohen, MD, Traces Evolution in CLL Therapy

Mary Caffrey
August 3rd 2023

Coverage from the July 25, 2023, session of the Institute for Value-Based Medicine®, held in partnership with Emory's Winship Cancer Institute.

Read More

Health data on computer

Researchers Deliver Updates on Efforts Toward Eradicating CLL

Christina Mattina
June 11th 2023

Panelists provided a wide-ranging view of the current avenues being investigated to optimize the treatment of chronic lymphocytic leukemia (CLL), including minimal residual disease assessment, combination regimens, and chimeric antigen receptor T-cell therapy.

Read More

Balancing pros and cons

Long-Term Data Show QOL Advantage of Zanubrutinib in 3 Cancers

Christina Mattina
June 10th 2023

Results from the ASPEN and ALPINE trials of zanubrutinib showed greater improvements in quality of life (QOL) vs ibrutinib.

Read More

<12
© 2024 MJH Life Sciences
AJMC®
All rights reserved.